|Day Low/High||95.00 / 97.28|
|52 Wk Low/High||64.72 / 126.98|
- FDA Accepts New Drug Application for Opicapone, a Once-Daily, Oral, Catechol-O-Methyltransferase (COMT) Inhibitor, as Adjunctive Therapy to Levodopa/Carbidopa
Conference Call and Webcast Scheduled for Monday, July 29
- INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia
Live Audio Webcast will be on June 11, 2019
Live Audio Webcast will be on June 6, 2019
- Nearly 30% of Patients with Possible Tardive Dyskinesia Reported Moderate-to-Extreme Problems Performing Their Usual Activities, Including Work, Housework and Leisure Activities
- RE-KINECT Analysis Provides Insight into the Impact of Possible Tardive Dyskinesia on Patient Health-Related Quality of Life
Live Audio Webcast will be on May 14, 2019
- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients
- Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease
- More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer
- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders
INGREZZA® (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx
Conference Call and Webcast Scheduled for Monday, April 29
- NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept
SAN DIEGO, March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following investor...
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:
Here are the top healthcare bets ticking all the boxes for analysts.
Stay active and selective: These are the five best stocks to invest in right now
Not every trade can be a winner, so let's lighten the load here.
Analysts weren't shy to defend the company after Tuesday's earnings.
Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.